Which hedge funds own PRLD? PRELUDE THERAPEUTICS INC, Q2 2026 13F holders
22 tracked hedge funds disclosed a position in PRLD (PRELUDE THERAPEUTICS INC) in their Q2 2026 13F filings, worth $220.5m in total. The largest holder by portfolio weight is Orbimed Advisors LLC at 1.4% of its book. 10 opened a new position this quarter: Soleus Capital Management, L.P., RA Capital Management, L.P., Spark Investment Management LLC, Hillsdale Investment Management Inc.. 4 exited: EcoR1 Capital, LLC, Diametric Capital, LP, NINE MASTS CAPITAL Ltd.
- 22
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 10
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 4
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $57.6m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $3.4m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $221m
- Combined value Sum of the holders' reported positions in the security.
- 1.8%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| EcoR1 Capital, LLC | 0.1% | $3.2m |
| Diametric Capital, LP | 0.01% | $41.0k |
| NINE MASTS CAPITAL Ltd | 0.01% | $40.0k |
| Point72 Asset Management, L.P. | 0.0% | $55.8k |
Ownership over time
Who discovered PRLD first? Beta
The run: Q2 2025 → Q2 2026, +559%
| Orbimed Advisors LLC high conviction | Q3 2020 | 0.2% | +0.4 pts |
| Baker Bros. Advisors LP | Q4 2020 | 0.08% | −1.3 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.